Time interval between diagnosis to treatment of breast cancer and the impact of health insurance coverage: a sub analysis of the AMAZONA III Study (GBECAM 0115).

Autor: Maschmann RM; Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245, Porto Alegre, Brazil.; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., De Jesus RG; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Werutsky G; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Rebelatto TF; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Queiroz G; Hospital Araújo Jorge, Goiás, Brazil., Simon SD; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Bines J; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.; Instituto Nacional do Câncer, Rio de Janeiro, Brazil., Barrios CHE; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Rosa DD; Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite, 245, Porto Alegre, Brazil. dornellesrosa@gmail.com.; Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil. dornellesrosa@gmail.com.; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil. dornellesrosa@gmail.com.; Hospital Moinhos de Vento, Porto Alegre, Brazil. dornellesrosa@gmail.com.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Feb; Vol. 198 (1), pp. 123-130. Date of Electronic Publication: 2022 Dec 31.
DOI: 10.1007/s10549-022-06809-8
Abstrakt: Purpose: Breast cancer (BC) is the most common type of cancer among women in Brazil. Evidence shows that delayed treatment onset is associated with increased mortality. This study aimed to evaluate median days between diagnosis and treatment and factors associated with delayed start of treatment (> 60 days after diagnosis): stage, treatment received, subtype, epidemiological characteristics, and type of healthcare coverage.
Methods: This analysis included 1709 stage I-III BC patients from AMAZONA III, a prospective, observational study, diagnosed from January 2016 to March 2018 in 22 centers in Brazil.
Results: The median number of days from diagnosis to beginning of first oncologic treatment was 46 days (IQR 28-75) overall, 43 days (IQR 25-75) for stage I disease, 49 days (IQR 28-81) for stage II, and 44 days (IQR 30-68) for stage III, (p = 0.1180). According to first treatment received, diagnosis-to-treatment interval was 43 days (IQR 29-65) for neoadjuvant chemotherapy and 48 days (IQR 26-81) for surgery. Diagnosis-to-treatment interval was higher in women treated in the public system versus the private system (56 vs. 34 days, p < 0.0001). Patients in the public system had an increased odds of delayed treatment initiation (OR 4.74 95% CI 3.09-7.26, p < .0001). The longer interval from diagnosis to treatment in the public system was independent of clinical stage, type of treatment (systemic vs surgery first), subtype and region of the country.
Conclusion: By characterizing the delays in care delivery, our study will aid stakeholders to better design interventions and allocate resource to improve timely treatment for breast cancer in Brazil.
Clinicaltrials: gov Identifier: NCT02663973, registered on January, 26th, 2016.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: